I. Introduction
Fungal infections are major cause of morbidity and mortality in the immunocompromised individuals and Candida are among the most common pathogens in these patients. The incidence of 6.9 per 1000 intensive care unit (ICU) patients and 7.5% of ICU patients received antifungal therapy was reported in the recent study. 1, 2 Growing population of immunocompromised patients and advances in medical and surgical managements has contributed an increase in candidaemia. Other associated risk factors causing fungal infections, include exposure to broad spectrum antimicrobial agents, mucosal colonisation by candida spp. Indwelling vascular catheters and premature infants. 3, 4 Candidaemia increases mortality rates in the range of 20-49%. 5, 6 The Candidaemia and invasive candidiasis are defined in general from diagnosis to prophylaxis, empiric and pre emptive strategies to treatment. So far, the scientific community has not been able to accurately predict invasive candidiasis and thus to define populations that benefit from prophylaxis or early treatment. Although it is well known that treatment is being initiated too late in the majority of patients, identification of the optimal time point to commence antifungal therapy remains challenging .7,8 Candida species belong to the normal microbiota of an individual's mucosal oral cavity, gastrointestinal tract and vagina are responsible for various clinical manifestations from mucocutaneous overgrowth to blood stream infections. 9 These yeast are commensal in the healthy human and may cause systemic infection in immunocompromised situations.
The genus Candida is composed of heterogeneous group of organisms and more than 17 different Candida species are known to be the aetiological agents of human infections, however, more than 90% of invasive infections are caused by C. albicans, C. tropicalis, C. glabrata, C. parapsilosis and C. krusei. 10 Systemic infections due to yeasts and resistance to antifungals is on the rise in Indian hospitals. 11 Candida albicans accounts for 40-60% of yeast isolates in the developed countries. 12 whereas Indian reports shows an increased predominance of C. non albicans isolates. 11 Increasing resistance to azoles and amphotericin B has been reported from India as well as from other countries. 11, 12 The potential clinical importance of species level identification has been recognised as Candida species differ in the expression of putative virulence factors and antifungal susceptibility. 13, 14 Rapid identification also guides early appropriate antifungal therapy. The aim of the present study is to identify the spectrum of Candida species in the clinical infections and to identify their sensitivity pattern to available antifungal agents.
II. Material And Method
The study period was from 15 Jan. 2016 to 15 July 2016. All type of samples obtained from the ICU patients admitted in tertiary care centre Bareilly. Clinical specimens were endotracheal aspirates, sputum, urine and blood. Blood culture samples collected in blood culture bottles were incubated in Bactec automated blood culture system ( Becton Dickinson, USA) and up on getting a positive alarm, were sub cultured on to sabouraud dextrose agar (HiMedia, India) and blood agar plate after getting gram positive budding yeast cells on gram stain of blood culture broth. All other specimens were inoculated on to Sabouraud dextrose agar plates in addition to blood agar, chocolate agar and MacConkey agar (HiMedia, India). Suspected colonies of Candida were confirmed by Gram stain and then Identified with vitek 2 Compact (Biomerieux, France) using vitek 2 cards for identification of yeast and yeast like organisms (ID-YST cards) Kits. Antifungal susceptibility testing was performed with AST YS07 Kits on Vitek 2 Compact. Standard operative procedures as described by the manufacturer were followed. The study was done with prior approval from institutional ethical research committee.
III. Result
A total of 89 isolates of Candida species were obtained from different clinical specimens of I.C.U patients. Out of them, 48 isolates were from urine specimen, 26 from endotracheal tube aspirates, 7 from blood and 8 from sputum. The distribution and percentage of different candida species in the 89 isolates are given in the table. Accordingly, the species isolated were C. albicans 28(31.46%), C. tropicalis 41(46.06%),C. guilliermondii 7(7.86%), C. krusei 4(4.49%), C. parasilopsis 3(3.3%), C. glabrata 2(2.24%), C. intermedia 2(2.24%), C. lipolytica 1(1.12%) and C. famata 1(1.12%) .We observed that invasive candidiasis is more frequently caused by non albicans candida species (68.53%) as compared to C. albicans(31.46%). The table 2 shows antifungal drug sensitivity pattern of Candida isolates in various samples.In this study antifungal drug sensitivity pattern of Candida isolates in various samples is following.
In the urine sample the candida albicans was 100% sensitive to fluconazole, voriconazole, amphotericin B and flucytosine except caspofungin and micafungin, both were 93.75% sensitive while non albicans candida is 75.0% sensitive to fluconazole, 96.8% to voriconazole, 87.5% to caspofungin. 87.5% to micafungin, 90.6% to amphotericin B and 81.25% sensitive to flucytosine. E.T. aspirate candida albicans is 100% sensitive to all antifungal drugs and non albicans candida species are 75% sensitive to fluconazole, 75% sensitive to voriconazole, 100% sensitive to caspofungin, 100% sensitive to micafungin, 75% sensitive to amphotericin B and 87.5% sensitive to flucytosine.
In blood all the candida albicans and non albicans candida isolates were 100% sensitive to all the antifungal drugs In sputum all candida albicans isolates were 100% sensitive to all antifungal drugs and non albicans candida isolates were 100% sensitive to all the antifungal drugs except amphotericin B which shows 83.3% sensitive. The 
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